Thomas MacAllister

Title: Thomas MacAllister: Innovator in Bioactive Therapeutics

Introduction

Thomas MacAllister is a notable inventor based in McLean, VA (US). He has made significant contributions to the field of bioactive therapeutics, particularly through his innovative research and patent in histidine ammonia lyase.

Latest Patents

MacAllister holds a patent for "Cloning, overexpression and therapeutic use of bioactive histidine ammonia lyase." This patent describes how histidine ammonia lyase (HAL), isolated from Corynebacteriaceae, can decrease serum histidine levels and induce the accumulation of urocanic acid. Notably, this enzyme is not inhibited by L-histidinol, making it uniquely suitable for combination therapy with L-histidinol. This therapy aims to treat histidine- and/or histamine-dependent pathologies, including infectious viruses such as human Respiratory Syncytial Virus (RSV), Herpes Simplex Virus (HSV), and Human Immunodeficiency Virus (HIV), as well as various cancers. MacAllister's work in this area has the potential to impact therapeutic strategies significantly.

Career Highlights

MacAllister is affiliated with the University of South Carolina, where he continues to advance his research in bioactive compounds. His innovative approach to therapeutic applications has garnered attention in the scientific community.

Collaborations

Throughout his career, MacAllister has collaborated with esteemed colleagues, including Natarajan Sethuraman and Joseph W. Roberts. These collaborations have enriched his research and contributed to the development of his patented technologies.

Conclusion

Thomas MacAllister's contributions to the field of bioactive therapeutics through his patent on histidine ammonia lyase highlight his innovative spirit and dedication to advancing medical science. His work promises to pave the way for new treatment options for various diseases.